Austrian company AOP Orphan Pharmaceuticals GmbH (AOP Health), a provider of integrated therapies for rare diseases and critical care, announced on Wednesday that the US Food and Drug Administration (FDA) has approved Rapiblyk (landiolol) for the treatment of supraventricular tachycardia, including atrial fibrillation and atrial flutter, in the critical care setting.

The approval was based on clinical trials demonstrating Rapiblyk's ability to rapidly reduce heart rate with minimal reduction of blood pressure.

This new treatment option will provide patients in the United States with a faster and more targeted approach to managing these conditions.